文献速递精神分裂症与精神病性障碍

精神分裂症谱系障碍个体治疗反应差异的meta分析

Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

该研究通过meta分析比较抗精神病药物随机对照试验中治疗组与对照组的结局变异,以评估个体治疗反应差异。

要点

  • 治疗组PANSS结局变异略低于对照组,变异比0.97(95%CI 0.95-0.99)。
  • 未发现抗精神病药物增加结局变异的证据,不支持个体化反应差异假设。
  • 平均治疗效应对于个体患者可能是合理假设,但无法排除部分患者反应不同。

核心结论

  • 在随机对照试验中未发现抗精神病药物增加结局变异的证据,提示不存在个体化治疗反应成分。
  • 研究无法排除部分患者对治疗反应不同,但总体不支持个体反应差异的假设。

研究设计与样本

  • 纳入双盲、安慰剂对照的随机对照试验,对象为诊断为精神分裂症谱系障碍并接受许可抗精神病药物处方的成人。
  • 提取阳性与阴性症状量表(PANSS)治疗前后结局差异评分的均数和标准差。
  • 采用逆方差法加权个体变异比,并纳入随机效应模型。

主要发现

  • 未发现抗精神病药物增加结局变异的证据。
  • 模拟随机对照试验包含30例患者随机分配至治疗组或对照组,用于说明变异成分。

关键数值与推荐

  • 主要结局指标为meta分析中治疗组与对照组总体变异比。

临床怎么用

  • 临床可基于平均治疗效应为个体患者制定抗精神病药物治疗方案。
  • 不应假设所有患者对治疗反应存在显著个体差异而常规进行个体化预测。
  • 对于部分可能反应不同的患者,仍需结合临床评估。

局限性

  • 研究无法排除 subsets of patients respond differently to treatment。
  • 研究仅纳入双盲安慰剂对照RCT,可能限制结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: An assumption among clinicians and researchers is that patients with schizophrenia vary considerably in their response to antipsychotic drugs in randomized clinical trials (RCTs). OBJECTIVE: To evaluate the overall variation in individual treatment response from random variation by comparing the variability between treatment and control groups. DATA SOURCES: Cochrane Schizophrenia, MEDLINE/PubMed, Embase, PsycINFO, Cochrane CENTRAL, BIOSIS Previews, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform from January 1, 1955, to December 31, 2016. STUDY SELECTION: Double-blind, placebo-controlled, RCTs of adults with a diagnosis of schizophrenia spectrum disorders and prescription for licensed antipsychotic drugs. DATA EXTRACTION AND SYNTHESIS: Means and SDs of the Positive and Negative Syndrome Scale pretreatment and posttreatment outcome difference scores were extracted. Data quality and validity were ensured by following the PRISMA guidelines. MAIN OUTCOMES AND MEASURES: The outcome measure was the overall variability ratio of treatment to control in a meta-analysis across RCTs. Individual variability ratios were weighted by the inverse-variance method and entered into a random-effects model. A personal element of response was hypothesized to be reflected by a substantial overall increase in variability in the treatment group compared with the control group. RESULTS: An RCT was simulated, comprising 30 patients with schizophrenia randomized to either the treatment or the control group. The different components of variation in RCTs were illustrated with simulated data. In addition, we assessed the variability ratio in 52 RCTs involving 15 360 patients with a schizophrenia or schizoaffective diagnosis. The variability was slightly lower in the treatment compared with the control group (variability ratio = 0.97; 95% CI, 0.95-0.99; P = .01). CONCLUSIONS AND RELEVANCE: In this study, no evidence was found in RCTs that antipsychotic drugs increased the outcome variance, suggesting no personal element of response to treatment but instead indicating that the variance was slightly lower in the treatment group than in the control group; although the study cannot rule out that subsets of patients respond differently to treatment, it suggests that the average treatment effect is a reasonable assumption for the individual patient.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Winkelbeiner S, Leucht S, Kane JM, et al. Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis. JAMA Psychiatry. 2019. PMID: 31158853. doi:10.1001/jamapsychiatry.2019.1530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。